Calypte und die Zeit nach AIDS2004 in Bangkok

go baby go gooooooooooooooooooooooooooooooooooooooooooooooooooooo  

Das hier hast du vergessen ...

"Today a White Marubozu was formed. This shows that the buyers controlled the price action from the first trade to the last trade."

;-)  

8-K/A
CALYPTE BIOMEDICAL CORP filed this Form 8-K/A on 12/20/04
 >


                                 UNITED STATES
                      SECURITIES AND EXCHANGE COMMISSION

                            WASHINGTON, D.C. 20549

                               FORM 8-K/A (NO.1)

               Current Report Pursuant to Section 13 or 15(d) of
                     the Securities Exchange Act of 1934

      Date of Report (Date of earliest event reported) September 28, 2004

                        CALYPTE BIOMEDICAL CORPORATION
              (EXACT NAME OF COMPANY AS SPECIFIED IN ITS CHARTER)



DELAWARE                                 000-20985                           06-1226727
--------                                 ---------                           ----------
                                                           
(STATE OR OTHER JURISDICTION)      (COMMISSION FILE NUMBER)        (I.R.S. EMPLOYER IDENTIFICATION)
OF INCORPORATION)


               5000 HOPYARD RD., SUITE 480, PLEASANTON CA 94588
               ------------------------------------------------
              (Address of principal executive offices) (Zip Code)

      Registrant's telephone number, including area code: (925) 730-7200
                                                          --------------

                                      N/A
                                      ---
         (Former name or former address, if changed since last report)

|_|   Written communication pursuant to Rule 425 under the Securities Act (17
     CFR 230.425)

|_|   Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR
     240.14a-12)

|_|   Pre-commencement communications pursuant to Rule 14d-2(b) under the
     Exchange Act (17 CFR 240.14d-2(b))

|_|   Pre-commencement communications pursuant to Rule 13e-4(c) under the
     Exchange Act (17 CFR 40.13e-4(c))




ITEM 1.01 ENTRY INTO A MATERIAL DEFINITIVE AGREEMENT

On September 28, 2004 the Registrant (the "Company"), Bio-Rad Laboratories, Inc.
("Bio-Rad") and Bio-Rad Pasteur entered into a non-exclusive license agreement
whereby the Company received a license to urine-based immunoassays and serum,
plasma, oral fluid or whole blood-based immunoassays having a composition
containing an HIV-2 antigen to be used by the Company in the development and
manufacture of its rapid tests.

On October 4, 2004, the Company filed a Current Report on Form 8-K reporting its
entrance into the non-exclusive license agreement with Bio-Rad and Bio-Rad
Pasteur. The Company hereby amends that report to include as an exhibit the
complete License Agreement between the parties.

ITEM 9.01 FINANCIAL STATEMENTS AND EXHIBITS

(c) Exhibits

10.152    License Agreement dated September 28, 2004 between Calypte, Bio-Rad
         Laboratories, Inc. and Bio-Rad Pasteur.

                                  SIGNATURES

Pursuant to the requirement of the Securities Exchange Act of 1934, the
Registrant has duly caused this report to be signed on its behalf by the
undersigned hereunto duly authorized.

Date:  Pleasanton, California
      December 17, 2004

                                       Calypte Biomedical Corporation

                                       By: /s/ Richard D. Brounstein
                                           ------------------------------------
                                           Richard D. Brounstein
                                           Executive Vice President and Chief
                                           Financial Officer





                                                                 Exhibit 10.152

                               LICENSE AGREEMENT

                 This License Agreement (hereinafter "Agreement"), effective as
of the  date of the last  signature  below  (the  "Effective  Date"),  is by and
between  Bio-Rad  Laboratories,  Inc.,  having an address at 1000  Alfred  Nobel
Drive,  Hercules,  California,  94547,  Bio-Rad Pasteur,  having an address at 3
Boulevard  Raymond  Poincare,  92430  Marnes-la-Coquette  France  (collectively,
"Licensor")  and  Calypte  Biomedical  Corporation,  having an  address  at 5000
Hopyard Road,  Suite 480,  Pleasanton,  California,  94588  ("Calypte")  (each a
"Party" and collectively, the "Parties")

                 WHEREAS,  Licensor has the right to grant a license  under the
Licensed Patents, as defined below;

                 WHEREAS,  Licensor  is willing to grant to Calypte and Calypte
desires  to obtain  from  Licensor a limited,  non-exclusive  license  under the
Licensed Patents;

                 NOW, THEREFORE, the Parties agree as follows:

1.       DEFINITIONS.

                 For the  purpose  of  this  Agreement,  the  terms  set  forth
hereinafter shall be defined as follows:

1.1      Affiliate

                 "Affiliate"  shall  mean,  with  respect  to  an  entity,  any
corporation or other business entity controlled by,  controlling or under common
control with such entity.  For purposes of this Paragraph 1.1,  "control"  shall
mean, with respect to an entity, direct or indirect beneficial ownership of more
than fifty percent (50%) of the voting stock or equity.

1.2      Licensed Patents

                 "Licensed Patents" shall mean those patents listed in Appendix
A and all divisions, continuations, continuations-in-part, and reissues of those
patents and all corresponding foreign counterparts to those patents.

1.3      Licensed Products

                 "Licensed Product(s)" shall mean Urine-based  immunoassays and
serum,  plasma,  oral fluid or whole  Blood-based  Immunoassays (i) which have a
composition  containing an HIV-2 antigen,  (ii) which are manufactured,  used or
sold by Calypte or its Affiliate and are capable of detecting HIV 1/2 antibodies
and/or  antigen only on Calypte's  Point of Care Rapid Test platform (as defined
in  Paragraph  1.5) and (iii)  which,  in the absence of this  Agreement,  would
infringe one or more Valid Patent Claims.




                 1.4 "Unit of  Licensed  Product(s)"  shall mean that part of a
Licensed Product that is required to test a single sample.

1.5      Calypte's Point of Care Rapid Test Platform

                 Calypte's  Point of Care  Rapid  Test  Platform  shall  mean a
lateral  flow  immuno-assay  developed,  manufactured  by or for  Calypte or an
Affiliate of Calypte for the rapid,  point-of-care  detection of  antibodies or
antigen to HIV-2 including any improvements or  modifications  that may be made
to such lateral flow, rapid test.

1.6      Point of Care

                 "Point   of   Care"   shall   mean   both   professional   and
over-the-counter point of care.

1.7      Territory

                 "Territory" shall mean worldwide.

1.8      Third Party

                 "Third  Party"  shall mean any party other than  Licensor  and
Calypte or their respective Affiliates.

1.9      Net Sales

                 "Net Sales" shall mean the gross amount invoiced by Calypte or
its  Affiliate  from  the sale of a  Licensed  Product  to a Third  Party in any
country within the Territory, less the following actually incurred by Calypte as
a result of such amounts invoiced:  (1) shipping costs,  insurance costs, custom
duties,  sales tax,VAT and rebates and returns (not to exceed 4% of total annual
Unit volume of Licensed  Products sold by Calypte).  Samples of Licensed Product
provided to end users free of charge shall also be excluded in  determining  Net
Sales  (total of such  items not to exceed  2% of total  annual  Unit  volume of
Licensed Products sold by Calypte).

                 If a  Licensed  Product  is sold in the form of a  combination
product  containing one or more assays that are not Licensed Products under this
Agreement,  Net  Sales  for such  combination  product  shall be  calculated  by
multiplying  actual  Net  Sales  of such  combination  product  by the  fraction
A/(A+B),  where A is the list  price in the  relevant  country  of the  Licensed
Product if sold separately and B is the total list price in the relevant country
of  any  other  assays  in  the  combination  if  sold  separately.   If,  on  a
country-by-country  basis,  the Licensed Product and other assays contained in a
combination  product are not sold  separately in such country,  the Net Sales of
such  combination  product shall be determined by  multiplying  the Net Sales of
such  combination  product  by the  fraction  A/(A+B),  where A is the number of
Licensed Products in the combination product and B is the number of other assays
in the  combination  product  that are not Licensed  Products.  The total of A+B
shall not exceed two (2).


                                     -2-



1.10     Valid Patent Claim

                 "Valid  Patent  Claim"  shall  mean a  claim  of an  unexpired
Licensed  Patent  that  has not been  revoked,  or held to be  unenforceable  or
invalid by a decision of a court or other  government  agency,  unappealable  or
unappealed within the time allowed for appeal.

2.       GRANTS

        Licensor  grants to  Calypte a  royalty-bearing  non-exclusive  license
(without the right to grant  sublicenses),  under the Licensed Patents, to make,
have made by its Affiliates only, use, import,  export,  offer to sell, and sell
and have sold the Licensed Products in the Territory under Calypte's brand name.
In addition, Licensor grants to Calypte a royalty-bearing  non-exclusive license
(without the right to grant  sublicenses),  under the Licensed Patents,  to have
the Licensed  Products made by Pacific  Biotech Co.,  LTD, 42 Moo 4 Napa,  Moung
Phetchaboon,  Thailand,  which shall be deemed an  Affiliate  for the purpose of
this Agreement.  Except as explicitly provided herein, Calypte does not have the
right to have the Licensed  Products  made by a Third  Party,  without the prior
written consent of Bio-Rad.

3.       FEES AND ROYALTIES, RECORDS AND REPORTS

        3.1 Within  thirty (30) days of the Effective  Date of this  Agreement,
Calypte shall pay to Licensor a license fee of $300,000.  This license fee shall
be non-refundable and not creditable toward royalties.

        3.2 Within six (6) months from the  Effective  Date of this  Agreement,
Calypte shall pay an additional  fee of $700,000 to Licensor.  This fee shall be
non-refundable and not creditable toward royalties.

        3.3

                          (a) Calypte  shall pay to Licensor  royalties  on Net
                 Sales of  Urine-based  Licensed  Products  sold in the  United
                 States,  Japan and Canada,  the greater of 15% of Net Sales of
                 Licensed Products or $0.30 per Unit of Licensed Product.

                          (b) Calypte  shall pay to Licensor  royalties  on Net
                 Sales of Urine-based  Licensed Products sold in any country in
                 the rest of the  world,  the  greater  of 10% of Net  Sales of
                 Licensed Products or $0.15 per Unit of Licensed Product.

        3.4

                          (a) Calypte  shall pay to Licensor  royalties  on Net
                 Sales  of  serum,  plasma  oral  fluid  or  whole  blood-based
                 Licensed Products sold in the United States,  Japan and Europe
                 (as defined in Appendix B), the greater of 15% of Net Sales or
                 $0.50 per Unit of Licensed Product.

                          (b) Calypte  shall pay to Licensor  royalties  on Net
                 Sales  of  serum,  plasma  oral  fluid  or  whole  blood-based
                 Licensed  Products  sold  in any  country  in the  rest of the
                 world,  the  greater  of 12% of Net Sales or $0.25 per Unit of
                 Licensed Product.


                                     -3-



        3.5

        Notwithstanding  any  contrary  provision  that may be contained in the
present  License  Agreement,  Calypte  agrees to pay the  royalties set forth in
Paragraph  3.3 and 3.4 on all Net Sales of  Licensed  Products  sold  before and
after  the  Effective  Date  of this  Agreement  in  every  country  within  the
Territory, regardless of the country of manufacture of Licensed Products.

        3.6 All  Royalty  payments  under  this  Agreement  shall  be paid on a
quarterly basis,  within sixty (60) days after March 31st, June 30th,  September
30th and December  31st of each year.  The first  royalty  payment shall include
payment of royalties due (if any) on Net Sales of Licensed Products prior to the
Effective  Date.  All payments shall be made in U.S.  dollars.  If Net Sales are
invoiced  in a  currency  other  than  U.S.  dollars,  then  such Net  Sales and
Calypte's royalty obligations based on such Net Sales shall be expressed in U.S.
dollars  converted on the basis of the average  daily New York foreign  exchange
rate for the thirty (30) day period ending on the payment date, as quoted in The
Wall Street Journal.

        3.7 Calypte  shall keep,  and shall require its  Affiliates  (including
Pacific  Biotech Co.) to keep,  full,  true,  and  accurate  books of account in
accordance  with  generally  accepted  accounting  principles  as applied in the
United States,  containing all particulars necessary to show the amounts due and
payable to Licensor under this  Agreement.  Such books and the  supporting  data
shall be open during normal  business hours upon reasonable  advance notice,  at
mutually  agreed  upon  times,  for  three (3)  years  following  the end of the
calendar year to which they pertain (and access shall not be denied  thereafter,
if reasonably  available),  to the inspection of an independent certified public
accountant retained by Licensor. If in dispute, such records shall be kept until
the dispute is settled.  Inspection shall be at Licensor's  expense,  unless the
inspector  concludes  that the  amount  payable  that is  stated  in a report is
understated  by five percent (5%) or more, in which case  Licensor's  reasonable
expenses  incurred in connection  with the inspection  shall be paid by Calypte.
The Parties  agree that any certified  public  accountant  inspecting  Calypte's
books  pursuant  to  this  Paragraph  3.7  shall  retain  as  confidential   all
information, including information about Calypte's finances and customers gained
as a result of that inspection,  with the exception that the accountant shall be
free to  communicate  information to Licensor with respect to (i) whether or not
Calypte is in compliance with the terms of this  Agreement,  (ii) the results of
the  audit  including  financial   information  but  not  customer  information,
information  relating to the accuracy of reports and payments made, and (iii) if
in the  accountant's  professional  opinion  Calypte is not complying or has not
complied with the terms of the Agreement,  the underlying  facts and information
relevant to said non-compliance. Such accountant shall be required to execute an
agreement with Calypte agreeing to the  confidentiality  provisions set forth in
this  Paragraph  3.7.  Information  disclosed  to  Licensor  as a  result  of an
inspection  shall be  subject  to the  confidentiality  provisions  set forth in
Paragraph 4.


                                     -4-



        3.8 Calypte  shall within sixty (60) days after March 31st,  June 30th,
September  30th and  December  Calypte  shall within sixty (60) days after March
31st,  June  30th,  September  30th  and  December  3lst  of  each  year of this
Agreement, deliver to Licensor a true and accurate written accounting report for
each calendar quarter. Each report, which must be acceptable to Licensor,  shall
in  particular  set forth,  per Licensed  Products  and on a  country-by-country
basis,  (i) the Net Sales,  (ii) all  deductions  from Net Sales made by Calypte
pursuant to Paragraph  1.9,  (iii) the royalties  payable by Calypte to Licensor
pursuant to Paragraph 3, (iv) the quantity of Licensed  Products  sold,  (v) the
name of Licensed Products sold, (vi) the Licensed Products catalog codes,  (vii)
the  quantity  of Units of  Licensed  Products  corresponding  to each  Licensed
Products  catalog code and, upon Licensor's  written request (viii) the quantity
of samples of Licensed Products provided to end users by Calypte.

        3.9  Simultaneously  with the delivery of each royalty report,  Calypte
shall pay to Licensor or to Licensor's  designee,  if designated in writing, the
monies then due under this Agreement for the period covered by the report.  Each
report shall be made and sent by the due date to the following addressees or any
other address that Licensor may provide in writing:

                      Bio-Rad Laboratories, Inc.
                      1000 Alfred Nobel Drive
                      Hercules, California 94547
                      Attention: General Counsel

                               and

                      Bio-Rad Pasteur
                      3 Boulevard Raymond Poincare
                      92430 Marnes-la-Coquette, France
                      Attention: Manager, Legal Affairs

        Each  payment  shall be made and sent by the due date to the  following
Bank Account (or to any other bank  account,  designee or address that  Licensor
may advise in writing):

                       Bank One, N.A.
                       Chicago, Illinois
                       ABA 071000013
                       For credit to Bio-Rad Laboratories, Inc.
                       Account # 58-86988

        3.10 If Calypte shall fail to pay any amount owing under this Agreement
by the due date, the amount owed shall bear interest at the Bank of America, San
Francisco,  California,  USA lending rate ("prime  rate") plus three (3) percent
from the due date until paid.

        3.11  Failure  of  Calypte  to pay  any  amount  specified  under  this
Agreement  within  thirty  (30) days after the due date will give  Licensor  the
right to terminate  this  Agreement  thirty (30) days after notice to Calypte of
the failure to pay which failure has not been cured within the latter thirty-day
period.


                                     -5-



        3.12 Calypte's  obligation to pay royalties  under this Section 3 shall
exist until the expiration of the last to expire of the Licensed Patents.

        3.13 In the event that any taxes,  withholding or otherwise, are levied
by any taxing  authority in connection  with accrual or payment of any royalties
payable to Licensor  under this  Agreement,  Calypte shall have the right to pay
such taxes to the local tax authorities on behalf of Licensor and the payment to
Licensor of the net amount  due,  after  reduction  by the amount of such taxes,
shall fully satisfy Calypte's royalty obligations under this Agreement, provided
that  appropriate  documentation  of such tax  payment,  including  evidence  of
payment  and  receipt or any other  appropriate  documentation,  is  provided to
Licensor.

4.       CONFIDENTIALITY

        4.1 The Parties shall maintain the confidentiality of the terms of this
Agreement  and shall not disclose the terms to any Third Party without the prior
written consent of the other Parties.  In addition,  Licensor shall maintain the
confidentiality  of any  information  disclosed  to  Licensor as a result of any
inspection  conducted under Paragraph 3.6 and shall use such information  solely
in connection  with this  Agreement.  The  confidentiality  obligations  in this
Paragraph 4 shall not apply where disclosure is required under applicable law or
regulation (including applicable securities laws or regulations),  in which case
the affected  Party shall notify the other Parties in writing in advance of such
disclosure and, upon request,  shall cooperate in seeking confidential treatment
of  the  disclosed  information.  The  Parties  agree  that  the  obligation  of
confidentiality shall also not apply if:

                 (a) the  information  is at the  material  time in the  public
domain through no fault of the receiving Party;

                 (b) the information is required by law to be communicated to a
person who is authorized by law to receive it;

                 (c) the  information  is  required  to be  provided to a stock
exchange, regulatory body or government agency;

                 (d) disclosure of the  information  is  necessarily  made to a
court, or to an arbitrator or administrative tribunal or to legal counsel in the
course of proceedings provided that, in the case of any arbitration proceedings,
Licensor or Calypte, as the case may be, first obtains from each and every party
to those proceedings an undertaking,  enforceable by Licensor or Calypte, as the
case may be, that each party will similarly not divulge or communicate,  without
Licensor  or  Calypte,  as the case may be,  written  consent,  any  information
referred to in this clause;

                 (e)  the  information  is  required  to be  disclosed  to  any
government  agency  whether in  connection  with the  granting of any license or
otherwise,  but such disclosure is to be made only with the consent of the Party
not disclosing the information; or

                 (f) the  disclosure  is made to  effect  registration  of this
Agreement with a Patent Office or other Industrial Property Authority.


                                     -6-



        4.2 All press  releases  relating to this  Agreement  shall require the
prior  approval of  authorized  representatives  of Licensor and Calypte,  which
approval shall not be unreasonably  withheld or delayed. The Parties acknowledge
that it is their intention to agree upon an appropriate  press release regarding
the signing of this Agreement.

5.       COMPLIANCE AND QUALITY

        5.1 In the exercise of any and all rights and in performance hereunder,
it shall be the duty of  Calypte  to  comply  fully  with all  applicable  laws,
regulations  and  ordinances  and to  obtain  and keep in effect  any  licenses,
permits and other governmental approvals (federal,  state or local) necessary or
appropriate to carry on Calypte's activities hereunder.

        5.2  Licensor  does not approve or endorse  Licensed  Products  sold by
Calypte in any way or for any purpose.  Quality and quality control according to
standards and requirements  that may exist in the marketplace from time to time,
are the sole responsibility of Calypte.

6.       ASSIGNMENT

                 This Agreement may not be assigned by Calypte, by operation of
law, merger, change in ownership or control, including acquisition of the assets
or change in  ownership  or control of the stock of  Calypte,  without the prior
written  consent of Licensor.  The term  "change in ownership or control"  shall
have the meaning set forth in Section 8.6.

7.       WARRANTY, NEGATION OF WARRANTIES AND INDEMNITY

        7.1  Licensor  warrants  that it has  the  right  to  enter  into  this
Agreement and grant the license granted to Calypte herein.

        7.2 Nothing in this Agreement  shall be construed as: (a) a warranty or
representation  by Licensor as to the validity or scope of any Licensed  Patent;
(b) a warranty or representation that the practice under the Licensed Patents is
or will be free from infringement of patents of Third Parties;  (c) an authority
or obligation to sublicense or to sue Third Parties for infringement; (d) except
as  expressly  set forth  herein,  conferring  the right to use in  advertising,
publicity or otherwise, in any form, the name of, or any trademark or trade name
of Licensor;  (e) conferring by implication,  estoppel or otherwise any license,
immunity or right under any patent  owned by or licensed to Licensor  other than
the  Licensed  Patents,  regardless  of  whether  such  patent  is  dominant  or
subordinate to the Licensed Patents;  (f) an obligation to furnish any know-how;
or (g) creating any agency,  partnership,  joint venture or similar relationship
between Licensor and Calypte.

        7.3 Licensor makes no express or implied  warranties of merchantability
or  fitness  for a  particular  purpose.  Licensor  shall not be liable  for any
consequential damages or lost profits of Calypte.

        7.4 Calypte shall assume full  responsibility  for its operation  under
the Licensed Patents and shall defend, indemnify and hold Licensor harmless from
and against all liability,  demands,  damages,  expenses  (including  reasonable
attorneys' fee) and losses for death, personal injury, illness,  property damage
or any other  injury or damage,  including  any damages or  expenses  arising in
connection  with  state  or  federal   regulatory   action,   arising  from  the
manufacture, use or sale of Licensed Products.


                                     -7-



        7.5 BioRad shall indemnify and hold Calypte,  its directors,  officers,
agents or  employees,  or any of its  Affiliates or their  directors,  officers,
agents  or  employees  (each,  a  "CALYPTE  PARTY")  harmless  from  any and all
liability,  damage,  loss,  cost  or  expense  (including,  without  limitation,
reasonable  attorneys'  fees and  expenses)  resulting  from any claims or suits
brought  against a Calypte  Party by a Third Party arising as a direct result of
(i) Bio-Rad's breach of any of the  representations or warranties made by BioRad
in this Agreement,  or (ii) any Third Party claim arising from Bio-Rad's  breach
of any of such representations or warranties.

        7.6 WITHOUT  LIMITING THE  INDEMNITY  OBLIGATIONS  OF EACH PARTY ABOVE,
NEITHER  PARTY  SHALL  BE  LIABLE  TO  THE  OTHER  PARTY  FOR  ANY   INCIDENTAL,
CONSEQUENTIAL, SPECIAL, OR PUNITIVE DAMAGES OF ANY KIND OR NATURE.

8.       TERM AND TERMINATION

        8.1 This  Agreement,  unless sooner  terminated in accordance  with its
terms, shall continue until the expiration of the last-to-expire of the Licensed
Patents.

        8.2 This  Agreement  shall  terminate  upon a holding of  invalidity or
unenforceability of all Licensed Patents by a final court decision from which no
appeal is or can be taken.

        8.3 This  Agreement  may be  terminated  by Calypte  by giving  written
notice to Licensor.  The termination shall be effective six (6) months after the
notice.  If  the  Agreement  is  terminated  by  Calypte,  Calypte  shall  cease
manufacturing  and selling  Licensed  Products as of the  effective  date of the
termination.

        8.4 The unappealable decision of a court or administrative body finding
Licensor  liable or culpable  due to Calypte's  manufacture  or sale of Licensed
Products  covered by this  Agreement  shall give Licensor the right to terminate
this  Agreement  immediately  upon  notice,  unless  Calypte  obtains a complete
release of Licensor and fully indemnifies Licensor for such liability.

        8.5 This Agreement  shall  terminate upon (i) an adjudication of either
Party as bankrupt or insolvent,  or admission in writing of its inability to pay
its  obligations as they mature;  (ii) an assignment of this Agreement by either
Party for the benefit of creditors;  (iii) the  appointment  of, or either Party
applying for or consenting to the appointment of, a receiver, trustee or similar
officer for a substantial  part of its property;  (iv) the institution of or any
act of either Party  instituting  any  bankruptcy,  insolvency  arrangement,  or
similar proceeding;  or (v) the issuance or levy of any judgment,  writ, warrant
of attachment or execution or similar process against a substantial  part of the
property of either Party. The Party causing such termination  under this Section
8.5 may apply for  reinstatement of this Agreement if either of conditions (iii)
or (v) is removed within ninety (90) days.


                                     -8-



        8.6 Unless prior  consent is given by Licensor,  Licensor may terminate
this Agreement immediately on notice upon any change in the ownership or control
of Calypte or of its  assets.  For such  purposes,  a "change  in  ownership  or
control"  shall  mean that 50% or more of the voting  stock of  Calypte  becomes
subject to the ownership or control of a person or entity,  or any related group
of persons or entities acting in concert, which person(s) or entity(ies) did not
own or  control  such  portion of voting  stock on the  Effective  Date  hereof.
Licensor shall have the same right to terminate upon any transfer of 50% or more
of the assets of Calypte.

        8.7 Upon any  breach  of or  default  of a  material  term  under  this
Agreement  by Calypte  (except for a payment  default  covered  under  Paragraph
3.11),  Licensor may terminate this Agreement upon sixty (60) days after receipt
of written  notice.  Licensor  will  withdraw  such notice if, during the notice
period, Calypte fully cures such breach or default.

        8.8 Upon  expiration  or  termination  of this  Agreement,  all  rights
granted to Calypte shall revert to or be retained by Licensor.

        8.9  Notwithstanding  the above, if Licensor  terminates this Agreement
for any reason other than an uncured payment  default by Calypte,  Calypte shall
have the right to dispose of its existing  inventory of Licensed Products and to
complete all outstanding  orders for Licensed Products for a period of up to six
(6) months  after the  effective  date of  termination;  provided  that  Calypte
fulfills its  obligations to report and pay royalties on such Licensed  Products
in accordance with this Agreement.

        8.10 Effect of Expiration or Termination

                 (a) Upon  termination of this  Agreement,  Licensor shall have
the right to retain any sums  already  paid by Calypte  hereunder,  and  Calypte
shall pay all sums accrued hereunder which are then due.

                 (b)  Paragraphs  3.7, 3.8,  3.9,  3.10, 4, 7.2, 7.4, 7.5, 7.6,
8.8,  8.9,  10.1 and 10.2 shall  survive any  termination  or  expiration of the
Agreement.

9. COUNTERPARTS

                 This  Agreement  may be signed in any number of  counterparts,
all of which taken together and when delivered shall constitute one and the same
instrument.  Any one of the Parties may enter into this Agreement by signing any
such counterpart.

10.      GENERAL

        10.1 This  Agreement  constitutes  the  entire  agreement  between  the
Parties as to the subject matter hereof, and supercedes all prior  negotiations,
representations,  agreements and understandings.  This Agreement may be modified
or amended only by a writing executed by authorized  representatives  of each of
the Parties.

        10.2 Any notice  required or  permitted  to be given by this  Agreement
shall be given by postpaid,  first class,  registered  or certified  mail, or by
courier,  properly  addressed to the other party at the  respective  address set
forth herein or another address that may be provided by written notice of either
Party to the other Party:


                                     -9-



                 If to Licensor:

                               Bio-Rad Laboratories, Inc.
                               1000 Alfred Nobel Drive
                               Hercules, California 94547
                               Attention: General Counsel

                                        and

                               Bio-Rad Pasteur
                               3 Boulevard Raymond Poincare
                               92430 Mames-la-Coquette France
                               Attention: Manager, Legal Affairs

                 If to Licensee:

                                Calypte Biomedical Corporation
                                5000 Hopyard Road, Suite 480
                                Pleasanton, CA 94588
                                Attention: Richard D. Brounstein
                                Executive Vice President

        10.3 Force Majeure

                 If the performance of any part of this Agreement by any Party,
or of any  obligation  under this  Agreement  (with the  exception of payment of
royalties),  is prevented, by reason of acts of God, fire, earthquakes,  acts of
war,  civil unrest or other similar cause beyond the control of the Party liable
to perform, unless conclusive evidence to the contrary is provided, the Party so
affected  shall,  upon giving written notice to the other Party, be excused from
such performance  provided that the affected Party shall use reasonable  efforts
to avoid or remove such causes of non-performance and shall continue performance
with  the  utmost  dispatch   whenever  such  causes  are  removed.   When  such
circumstances arise, the Parties shall discuss what, if any, modification of the
terms of this  Agreement  may be  required  in order to arrive  at an  equitable
solution.

11.      GOVERNING LAW AND VENUE.

        11.1 This Agreement  shall be construed and enforced in accordance with
the laws of the State of California,  USA without giving effect to its conflicts
of law principles.  The Parties agree that the exclusive  jurisdiction and venue
for any dispute or controversy  arising from this Agreement  shall be the courts
in California, USA.

        11.2 If any  provision of this  Agreement is held or  discovered  to be
illegal,  invalid or unenforceable in any jurisdiction,  all other provisions of
this  Agreement  shall be  deemed  valid  and  enforceable  to the  full  extent
possible.


                                     -10-




                 IN WITNESS  WHEREOF,  Licensor and Calypte have  executed this
Agreement as of the date of the last signature below.



                                         
BlO-RAD PASTEUR                               CALYPTE BIOMEDICAL CORPORATION

By:  /s/ Patrick Bugeon                       By: /s/ Richard D. Brounstein
    ----------------------------------           -------------------------------------

Name:  Patrick Bugeon                         Name: Richard D. Brounstein
     -------------------------------               ---------------------------------

Title:   CEO                                  Title:  Executive Vice President and Chief
                                             Financial Officer
Date:  September 7, 2004
     ------------------
                                             Date: August 23, 2004
                                             For Consent Only:
BlO-RAD LABORATORIES, INC.                    INSTITUT PASTEUR

By: /s/ Sanford S. Wadler                     By: /s/ C. Policard
   -----------------------------------           ------------------------------------

Name: Sanford S. Wadler                       Name:  C. Policard
                                                   ------------

Title: Vice President and General Counsel     Title: EVP Business Development
                                                    --------------------------------

Date: 9/28/04                                 Date: Feb. 17, 2004
     -------------------------------               --------------------------------




                                     -11-



                               LICENSE AGREEMENT

                                  APPENDIX A

LICENSED PATENTS

HIV-2 (Foundational)

EP 0239 425
EP 0 320 495
EP 284 383
EP 283 327
US 4,839,288
US 5,030,718
US 5,055,391
US 5,066,782
US 5,268,265
US 5,364,933
US 5,051,496
US 5,770,703
US 5,830,641
US 5,079,342
US 6,048,685
US 6,162,439
US 6,261,762
US 6,265,149
US 6,322,964
US 5,306,614
US 5,580,739
US 6,518,015



                                 Appendix A-1



                               LICENSE AGREEMENT

                                  APPENDIX B

Countries comprising Europe:

Andorra                         Macedonia                          
Austria                         Malta                              
Belarus                         Moldova                            
Belgium                         Monaco                              
Bosnia and Herzegovina          Netherlands                        
Bulgaria                        Norway                              
Croatia                         Poland                              
Czech Republic                  Portugal                            
Denmark                         Romania                            
Estonia                         Russia                              
Finland                         San Marino                          
France                          Slovakia                            
Germany                         Slovenia                            
Greece                          Spain                              
Hungary                         Sweden                              
Iceland                         Switzerland                        
Ireland                         Turkey                              
Italy                           Ukraine                            
Latvia                          United Kingdom                      
Liechtenstein                                                      
Lithuania                       Vatican City                        
Luxembourg                      Yugoslavia (Serbia and Montenegro)  
                               




Gruß

c.O



 

erklärt auch so einiges warum die das ganze verzögert haben...

Good Xmas


Gruß

C.O
 

SECURITIES AND EXCHANGE COMMISSION

                            Washington, D. C. 20549

                                --------------

                              FORM 10-QSB/A NO. 1

                                --------------
(Mark One)

[X]   QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15 (d) OF THE SECURITIES
     EXCHANGE ACT OF 1934

                 For the quarterly period ended June 30, 2004

                                      OR

[ ]   TRANSITION REPORT PURSUANT TO SECTION 13 OR 15 (d) OF THE SECURITIES
     EXCHANGE ACT OF 1934

     For the transition period from                 to                
                                    ---------------    ---------------

Commission file number:   000-20985

                        CALYPTE BIOMEDICAL CORPORATION
            (Exact name of registrant as specified in its charter)

                 DELAWARE                                    06-1226727
(State or other jurisdiction of incorporation              (I.R.S. Employer
             or organization)                          Identification Number)

                         5000 HOPYARD ROAD, SUITE 480
                             PLEASANTON, CA 94588
              (Address of principal executive offices ) (Zip Code)

                                (925) 730-7200
             (Registrant's telephone number, including area code)

        Indicate by check mark whether the registrant (1) has filed all reports
required to be filed by Section 13 or 15(d) of the  Securities  Exchange  Act of
1934  during  the  preceding  12 months  (or for such  shorter  period  that the
registrant was required to file such reports),  and (2) has been subject to such
filing requirements for the past 90 days.

                              Yes [X]      No [ ]

        The registrant had 168,044,755 shares of common stock outstanding as of
August 6, 2004.

==================================================




                CALYPTE BIOMEDICAL CORPORATION AND SUBSIDIARIES

                             FORM 10-QSB/A (NO.1)

                                     INDEX


                                                                       PAGE NO.
                                                                       --------


PART II.   OTHER INFORMATION




Item 6.        Exhibits and Reports on Form 8-K.........................   3

SIGNATURES .............................................................   4



                                     - 2 -




                CALYPTE BIOMEDICAL CORPORATION AND SUBSIDIARIES




ITEM 6.     EXHIBITS AND REPORTS ON FORM 8-K

a.       Exhibits

        10.150   Sublicense Agreement between the Company and Abbott
                 Laboratories dated June 28, 2004.

         31.1    Certification of Chief Executive Office pursuant to Section
                 302 of the Sarbanes-Oxley Act of 2002

         31.2    Certification of Chief Financial Officer pursuant to Section
                 302 of the Sarbanes-Oxley Act of 2002.

b. Reports on Form 8-K

        Form 8-K regarding Item 5. Other Materials Events, filed April 9, 2004
                 - Announcement of the appointment of Maxim A. Soulimov,
                 Director of Legal Affairs of Global Corporate Ventures Ltd.,
                 as a member of the Company's Board of Directors effective
                 April 2, 2004, including the Company's press release dated
                 April 6, 2004.

        Form 8-K regarding Item 5. Other Materials Events, filed June 1, 2004 -
                 Announcing the completion of a $9.3 million private placement
                 of the Company's common stock to accredited investors on May
                 28, 2004, including the Company's press release dated June 1,
                 2004.

        Form 8-K/A (No. 1) regarding Item 5. Other Materials Events, filed June
                 3, 2004 - Announcing the second amendment of the Marr Credit
                 Facility resulting in a commitment by Marr Technologies BV to
                 purchase up to $5,000,000 of 9% promissory notes that the
                 Company may issue during the period June 1, 2004 through
                 December 31, 2004.

        Form 8-K regarding Item 5. Other Materials Events, filed June 24, 2004
                 - Announcing the quality certification to ISO Standard 13485
                 received by the Company's Rockville, MD manufacturing facility
                 and the relocation of the Company's headquarters offices to
                 Pleasanton, California following the closure of its Alameda,
                 California operations.

        Form 8-K regarding Item 5. Other Material Events, filed July 1, 2004 -
                 Announcing the resignation of Zafar I. Randawa, Ph.D. as a
                 member of the Company's Board of Directors effective June 30,
                 2004.



                                     - 3 -







                                  SIGNATURES


    Pursuant to the  requirements  of the Securities  Exchange Act of 1934, the
Registrant  has duly  caused  this  report  to be  signed  on its  behalf by the
undersigned thereunto duly authorized.


                               CALYPTE BIOMEDICAL CORPORATION
                               (Registrant)




Date: December 17, 2004         By: /s/ Richard D. Brounstein            
                                   -------------------------------------------
                                   Richard D. Brounstein
                                   Executive Vice President and Chief Financial
                                   Officer (Principal Accounting Officer)



                                     -4-








                                                                 Exhibit 10.150

                             SUBLICENSE AGREEMENT

        This  Sublicense  Agreement (the  "Agreement") is entered into and made
effective this 28 day of _June___________, 2004, (the "EFFECTIVE DATE") between,
Calypte Biomedical Corporation, a Delaware corporation, whose principal place of
business is at 1265 Harbor Bay Parkway,  Alameda,  California 94502 (hereinafter
referred to as  "CALYPTE")  and Abbott  Laboratories,  an Illinois  corporation,
whose  principal  place of  business is at 100 Abbott  Park Road,  Abbott  Park,
Illinois 60064-3500 (hereinafter referred to as "ABBOTT").

         For and in  consideration  of the mutual  promises and  covenants  set
forth below, CALYPTE and ABBOTT agree as follows:

         1.0     DEFINITIONS.

         1.1  "AFFILIATE"  shall mean any  corporation or other business entity
controlled by,  controlling or under common control with the recited entity. For
this purpose  "control"  shall mean direct or indirect  beneficial  ownership of
more than fifty percent (50%) of the voting stock of, or more than fifty percent
(50%) interest in the income of such  corporation  or other business  entity and
the ability to direct the conduct of its business affairs on a regular basis.

        1.2 "AUTHORIZED  RETAILER" shall mean any person or entity which is not
an AFFILIATE who sells only to a CONSUMER.

        1.3 "CONSUMER"  shall mean a final purchaser of a PRODUCT who purchases
for the purpose of  diagnosis  of  themselves  or their  friends or family.  

        1.4  "EXCLUDED   ENTITY"  shall  mean,   Inverness   Medical,   OraSure
Technologies, Bayer, Beckman Coulter or their Affiliates, successors or assigns.

1.5      "FIELD" shall mean human in vitro diagnostics.


                                      1




        1.6  "LICENSED   PATENT(S)"   shall  mean  United  States  Patent  Nos.
5,073,484,  5,654,162 and 6,020,147;  any patents resulting from a reexamination
or reissue from any of the foregoing patents; and any patents, whether issued in
the  United  States or any other  country,  which  result  from an  application,
whether a continuation,  continuation-in-part,  division,  foreign equivalent or
any other type,  claiming  priority  from US  Application  Serial Nos.  356,459;
467,229;  607,794;  891,932;  574,607;  and/or 891,864 to Swanson, et al. and/or
Guire, et al., including but not limited to the patent applications set forth in
Appendix A.

        1.7 "PRODUCT(S)" shall mean any product,  device,  instrument,  kit, or
component thereof, the making, using,  importing,  or selling of which would, in
the absence of the sublicense  granted  hereunder,  infringe,  contribute to the
infringement of, or induce the infringement of any claim of a LICENSED PATENT.

        1.8 (a) "NET SALES" shall equal an amount calculated,  unless otherwise
specified  in this  Section  1.8,  using,  as  elected  by  CALYPTE,  one of the
following  alternative methods: (i) the amount charged by an AUTHORIZED RETAILER
for  the  sale to a  CONSUMER  of the  PRODUCT  sold  by  CALYPTE  or one of its
AFFILIATES  in the United  States of  America,  or (ii) an amount  equal to 1.67
times the amount charged by CALYPTE or one of its AFFILIATES to an  unaffiliated
party for the sale of the PRODUCT to a CONSUMER in the United States of America;
provided, however, when a PRODUCT is sold by CALYPTE or one of its AFFILIATES in
the same  geographic  market to both  AUTHORIZED  RETAILERS and  WHOLESALERS the
amount charged to the AUTHORIZED  RETAILERS  shall be used as the amount charged
to both  AUTHORIZED  RETAILERS  and  WHOLESALERS  in  calculating  this  Section
1.8(a)(ii)  the NET  SALES  for such  sales.  CALYPTE  shall  have the  right to
subtract from the NET SALES of a PRODUCT,  each of the following,  to the extent
they  are  applicable  to the sale of the  PRODUCT,  an  amount  equal  to:  (1)
discounts to in (i) above  Consumers  and in (ii) above the  unaffiliated  party
allowed and taken in connection with the sale of the PRODUCT, (2) transportation
or shipping charges included in (i) above in the amount charged to the Consumers
and in (ii) above in the amount charged to the  unaffiliated  party, (3) amounts
repaid,  credited or rebated by CALYPTE or one of its AFFILIATES in (i) above to


                                      2




Consumers  and in (ii) above to the  unaffiliated  party due to a  rejection  or
return of the PRODUCT,  and (4) taxes and duties  included in the amount charged
in (i) above to  Consumers  and in (ii) above to the  unaffiliated  party.  (The
foregoing are hereinafter collectively referred to as the "Deductions".) Samples
of  PRODUCTS  provided  free of  charge  and  PRODUCTS  used  for  research  and
development  programs,  or government or regulatory  purposes,  or  preclinical,
clinical and field trials, shall also be excluded in determining NET SALES.

                 (b) When a PRODUCT is sold by CALYPTE or one of its AFFILIATES
to a purchaser with which the seller does not deal at arms length, the NET SALES
for that  PRODUCT  shall  equal an average of the NET SALES,  as  calculated  by
CALYPTE using Section 1.8(a) above, for similar  PRODUCTS sold,  within the same
calendar  quarter as the  PRODUCT,  to  unaffiliated  purchasers  in arms length
transactions  who are in the same  geographic  market and class of purchasers as
the non-arms length purchaser.

                 (c) When a PRODUCT is not sold, and is not a free  replacement
or sample,  but is OTHERWISE DISPOSED OF (as defined in Section 1.10 below), the
NET SALES of that PRODUCT shall equal an average of the NET SALES, as calculated
by CALYPTE using Section 1.8(a) above,  for similar  PRODUCTS  sold,  within the
same  calendar  quarter  as the  PRODUCT  that  is  OTHERWISE  DISPOSED  OF,  to
unaffiliated  purchasers  in  arms  length  transactions  who  are in  the  same
geographic market in which the PRODUCT was OTHERWISE DISPOSED and the same class
of purchasers to whom the PRODUCT was OTHERWISE DISPOSED.

                 (d) (i) When packaged with other products or assays which have
commercial  utility  other than in  combination  with the  PRODUCT (a  "Packaged
Product"),  and the  PRODUCT  is not  separately  priced,  the NET SALES of that
PRODUCT shall equal an amount  calculated by  multiplying  the amount charged by
CALYPTE or one of its AFFILIATES  for the sale of the Packaged  Product less the
applicable  Deductions  times a fraction,  the  numerator  of which shall be the
average of the NET SALES, as calculated by CALYPTE using Section 1.8(a) above or
Section  1.8(g) below,  whichever is  appropriate,  for similar  PRODUCTS  sold,
without such other products or assays,  within the same calendar  quarter as the
sale of the Packaged Product,  to unaffiliated third parties located in the same
geographic market in which the Packaged Product was sold, and the denominator of
which  shall be the  average of the amounts  charged,  within the same  calendar
quarter as the sale of the  Packaged  Product,  to  unaffiliated  third  parties
located the same geographic  market in which the Packaged  Product was sold less
the applicable  Deductions.  In the event that there is no established NET SALES
for the  PRODUCT  when sold  without  such  other  products  or assays  then the
fraction  shall be a number  whose  numerator  shall be the average of the fully


                                      3




burdened  costs, as established by the cost  accounting  records of CALYPTE,  to
manufacture all non packaged PRODUCTS,  similar to the PRODUCT that was included
in the Packaged Product,  that were manufactured in the same calendar quarter in
which the Packaged Product was sold and whose  denominator  shall be the average
of the fully burdened costs to manufacture all Packaged  Products similar to the
Packaged  Product that were  manufactured in the same calendar  quarter in which
the Packaged Product was sold.

                          (ii) In the event  the  Packaged  Product  is sold by
CALYPTE or one of its AFFLIATES to an AUTHORIZED  RETAILER or WHOLESALER and the
NET SALES is calculated using Section 1.8(d)(i), it shall be multiplied by 1.67;
provided,  however,  when a  Packaged  Product  is sold by CALYPTE or one of its
AFFILIATES  in the same  geographic  market  to both  AUTHORIZED  RETAILERS  and
WHOLESALERS  the amount  charged to the  AUTHORIZED  RETAILERS  shall be used in
calculating  the Section  1.8(d)(i)  the NET SALES for the sale of the  Packaged
Product to WHOLESALERS.


                                      4




                 (e) In the event that a PRODUCT is  incorporated  into a total
package in which said PRODUCT  contributes  only a small proportion of the value
of the total package, but the adjustment set forth hereinabove in Section 1.8(d)
is  impractical,  the parties  shall  negotiate  in good faith to  establish  an
equitable  adjustment  to the NET SALES for such  PRODUCT to fairly  reflect the
proportion  of the  value  of the  total  package  contributed  by the  PRODUCT.
However,  in no case will the value be  attributed  to the PRODUCT which exceeds
that  obtained by using a factor,  the numerator of which shall be the number of
results  obtained  from the  PRODUCT and the  denominator  of which shall be the
total number of results provided by the total package.

                 (f) In the instance in which  PRODUCT is increased in price to
include an amount to cover  amortized cost of an instrument  system and/or other
equipment and the cost of supplying maintenance for such system and/or equipment
under a Reagent  Agreement  Plan,  Reagent  Rental Plan,  or other  successor or
similar plan (collectively  referred to herein as "RAP"), the NET SALES for such
PRODUCT  sold under RAP shall be  determined  by reducing the total NET SALES of
such PRODUCT  (including the total of sale of PRODUCT and instrument system RAP)
by the amount of the price  increase  attributable  to RAP, in  accordance  with
standard  CALYPTE  accounting  procedures  actually used by CALYPTE in its usual
course of  business  to assess the  results  of its  operations  concerning  the
PRODUCT  which  procedures  shall  be  in  accordance  with  generally  accepted
accounting principles, provided that the amount attributable to the NET SALES of
the PRODUCT shall be no less than the average of the NET SALES, as calculated by
CALYPTE using Section 1.8(a) above, for similar  PRODUCTS sold,  within the same
calendar  quarter as the sale of the PRODUCT sold under the RAP, to unaffiliated
non-RAP  customers  located in the same  geographic  market in which the PRODUCT
under the RAP was sold.

                 (g) With respect to sales of any PRODUCT  whose  intended user
by virtue of  labelling  or  marketing  is other than a  CONSUMER  in the United
States of America (e.g., other than an OTC PRODUCT in the USA), the NET SALES of
the  PRODUCT  shall  equal the amount  charged for the PRODUCT by CALYPTE or its


                                      5




AFFILIATES to a non-affiliated third party, less (i) discounts allowed and taken
by the  non-affiliated  third party, (ii) amounts for transportation or shipping
included in the amount  charged to the  non-affiliated  third party  purchasers,
(iii) amounts repaid,  credited or rebated to the non-affiliated  third party by
reason of a  rejection  or  return of the  PRODUCT,  and (iv)  taxes and  duties
included in the amount charged to the  non-affiliated  third party for PRODUCTS.
Samples of PRODUCTS  provided  free of charge and PRODUCTS used for research and
development  programs,  or government or regulatory purposes, or preclinical and
clinical  trials and field  trials  shall also be  excluded in  determining  NET
SALES.

        1.9 "OTC  PRODUCT"  shall  mean a human in  vitro  diagnostics  product
labeled for sale or marketed to a CONSUMER.

        1.10     "OTHERWISE DISPOSED OF" shall mean and include:

                 (a) the  delivery  of any amount of  PRODUCT,  other than free
replacements,  nominal  quantities of free samples or PRODUCTS used for research
and development  programs, or government or regulatory purposes, or preclinical,
clinical and field trials,  by CALYPTE to others in any transaction other than a
sale, regardless of the basis of consideration, if any; or

                 (b) the  placing  into use of any  PRODUCT by CALYPTE  for any
purpose,  other than its  internal  routine  testing or as  provided  in Section
1.10(a)  above,  provided that the scrapping or destruction of any PRODUCT shall
not fall  within  the  definition  of  "OTHERWISE  DISPOSED  OF" and no value in
respect thereof shall be included in calculating the NET SALES of the PRODUCT. A
PRODUCT shall be considered OTHERWISE DISPOSED OF when used or shipped by, or on
behalf of, CALYPTE.


                                      6




        1.11  "CALENDAR  QUARTER"  shall mean any  period of three  consecutive
calendar months  beginning  January 1, April 1, July 1, and October 1, occurring
during the term of this Agreement.

        1.12  "WHOLESALER"  shall  mean any  person or entity to which  CALYPTE
sells PRODUCT for resale to an AUTHORIZED RETAILER.

        2.0      LICENSE GRANT AND RELEASE.

        2.1 Subject to the terms and conditions herein, ABBOTT hereby grants to
CALYPTE  and  its   AFFILIATES,   who  accepts   the  same,   a   non-exclusive,
non-transferable, right and sublicense under the LICENSED PATENTS, to make, have
made for its own use and  sale,  use,  offer to sell,  sell and  import  PRODUCT
within the FIELD,  with the  exception  that CALYPTE  shall be  prohibited  from
selling or making OTC  PRODUCT  for an  EXCLUDED  ENTITY,  and to  practice  the
methods claimed in the LICENSED PATENTS in connection with such PRODUCT,  and to
extend to its customers purchasing PRODUCT the right to use and sell the PRODUCT
purchased  and to  practice  the  methods  claimed  in the  LICENSED  PATENTS in
connection  with such  PRODUCT  in the FIELD.  For  clarification,  the  license
granted  in this  Section  2.1 shall  include  rights to make and sell  PRODUCTS
through an Original  Equipment  Manufacturer  ("OEM") and under label other than
CALYPTE's  or  its  AFFILIATE's,  with  the  exception  that  CALYPTE  shall  be
prohibited  from making and selling OEM products and products under labels of an
EXCLUDED ENTITY.

        2.2 ABBOTT further hereby releases CALYPTE and its AFFILIATES,  and its
and their  customers  from any  liability for any  infringement  of the LICENSED
PATENTS arising from activities which occurred prior to the EFFECTIVE DATE.

        3.0      TERM.

        3.1 This  Agreement  shall become  effective as of the  EFFECTIVE  DATE
hereof and shall  continue  in effect  until the last to expire of the  LICENSED
PATENTS.


                                      7




        4.0      PAYMENT.

        4.1 In consideration for the sublicense and release granted  hereunder,
CALYPTE shall pay or cause to be paid to ABBOTT:

                 (a) A  non-refundable  fee of  two  hundred  thousand  dollars
($200,000.00)  in two  installments,  the first  installment  of fifty  thousand
dollars ($50,000.00) shall be due within thirty (30) days of the EFFECTIVE DATE,
and the second  installment of one hundred fifty thousand dollars  ($150,000.00)
shall be due upon the  earlier  of (i)  within  thirty  (30)  days of the  first
commercial  sale of  PRODUCT,  or (ii) on or before  December  31,  2005;

                 (b) A  royalty  at the rate of six  percent  (6.0%) of the NET
SALES of each OTC PRODUCT sold or OTHERWISE  DISPOSED OF on or subsequent to the
EFFECTIVE DATE in the United States of America;

                 (c) A  royalty  at the rate of six  percent  (6.0%) of the NET
SALES of each  PRODUCT  sold or OTHERWISE  DISPOSED OF on or  subsequent  to the
EFFECTIVE DATE, other than the OTC PRODUCTS accounted for in Section 4.1(b); and

                 (d) An  annual  minimum  royalty  of twenty  thousand  dollars
($20,000.00) per calendar year beginning January 1, 2004.

        4.2 It is expressly  understood  that more than one (1) LICENSED PATENT
may issue in a country.  However,  in no event  shall the total  royalty for any
PRODUCT made,  used, or sold after the EFFECTIVE  DATE exceed the amounts stated
in Section 4.1(b)  hereinabove,  regardless of where such PRODUCT is made, used,
or sold.

        4.3 CALYPTE's  obligation to pay royalties under Section 4.1 on PRODUCT
shall only extend to PRODUCT whose manufacture,  sales or use at the time of its
manufacture  or sale is subject to an  enforceable  claim of a LICENSED  PATENT.
Thus,  this obligation  shall terminate with regard to activities  undertaken by
CALYPTE in a given country after the expiration or lapse of the LICENSED PATENTS
with  claims  covering  this  activity  in that  country.  If all the  claims of
LICENSED  PATENTS covering the activities of CALYPTE in a given country shall be


                                      8




held unenforceable or invalid by the competent authorities in that country, then
CALYPTE  shall  have no  obligation  with  regard  to such  activities  unless a
decision not subject to appeal becomes final which  reverses this  determination
with regard to at least one claim covering such activities  during the period in
which the patents were held invalid or unenforceable.  If at least one (1) claim
covering such activities is decided valid and enforceable,  CALYPTE will pay the
appropriate  royalties for such  activities  within sixty (60) days after ABBOTT
notifies CALYPTE that such decision has become final.

                 Upon the written  request of CALYPTE,  ABBOTT  shall  promptly
inform CALYPTE when any claim of a LICENSED  PATENT  expires,  lapses or becomes
subject to a final decision of invalidity or unenforceability.

        4.4 No royalty shall accrue or become due more than once for a PRODUCT.

        4.5 For all sales and  royalty-bearing  transfers and uses occurring on
or subsequent to the EFFECTIVE  DATE,  CALYPTE shall provide  written reports to
ABBOTT within sixty (60) days after the end of each CALENDAR QUARTER, stating in
each report for each  different type of PRODUCT sold,  OTHERWISE  DISPOSED OF or
given away as free samples or replacements during such CALENDAR QUARTER: (i) the
number of PRODUCTS  sold,  (ii) the number of PRODUCTS  OTHERWISE  DISPOSED  OF,
(iii) the number of PRODUCTS  given away as free samples or  replacements,  (iv)
the name or names of the analytes for which the PRODUCT is testing,  and (v) the
total of the NET SALES of PRODUCT sold.

        4.6 (a)  Concurrently  with the making of each report CALYPTE shall pay
to ABBOTT all royalties due, in the amount  specified in Section 4.1(b) and (c),
on the PRODUCTS included in the report.


                                      9




                 (b) Any late  payment  shall bear  interest at the rate of one
percent (1%) per month.

        4.7 All  payments  shall be made  hereunder in United  States  Dollars;
provided,  however,  that if the  proceeds of the sales upon which such  royalty
payments are based are  received by CALYPTE in a foreign  currency or other form
that is not  convertible or exportable in United States  Dollars,  CALYPTE shall
pay such  royalties in the currency of the country in which such sales were made
by depositing  such royalties in ABBOTT's name in a bank designated by ABBOTT in
such country. Royalties in United States Dollars shall be computed by converting
the  royalty  in the  currency  of the  country  in which the sales were made in
accordance with the procedures  ordinarily used by CALYPTE in converting foreign
currency sales in its normal business  operations,  which procedures shall be in
accordance with generally accepted accounting principles.

        4.8 In the event that any taxes,  withholding or otherwise,  are levied
by any taxing  authority in connection  with accrual or payment of any royalties
payable to ABBOTT under this agreement, CALYPTE shall have the right to pay such
taxes to the local tax authorities on behalf of ABBOTT and the payment to ABBOTT
of the net amount due, after reduction by the amount of such taxes,  shall fully
satisfy  CALYPTE's  royalty  obligations  under this  Agreement,  provided  that
appropriate documentation of such tax payment, including evidence of payment and
receipt or any other appropriate documentation, is provided to ABBOTT.

        4.9 All payments made hereunder  shall be made to ABBOTT at the address
set forth in Article 6.0 of this Agreement or at such changed  address as ABBOTT
shall specify by written notice.

        4.10 CALYPTE shall keep records sufficient in accordance with generally
accepted  accounting  principles  to  permit  verification  of the  reports  and
payments  made to ABBOTT  hereunder  regarding  all  PRODUCT  sold or  OTHERWISE
DISPOSED OF. Records relating to the NET SALES of a PRODUCT sold in any CALENDAR
QUARTER after the EFFECTIVE  DATE shall be available for  inspection for two (2)


                                      10




years after the close of that CALENDAR QUARTER.  At ABBOTT's expense and request
and upon reasonable notice,  CALYPTE shall permit such records to be examined by
independent public accountants designated by ABBOTT and reasonably acceptable to
CALYPTE.  Such accountants  shall report only the amount by which royalties have
been overpaid or underpaid and shall make such report  simultaneously to CALYPTE
and  ABBOTT.  All  information  acquired  in  the  course  of  such  audits  and
inspections,  except  the  amount  of  royalties  due  ABBOTT,  shall be  deemed
confidential  information  of CALYPTE and shall not be disclosed to ABBOTT,  and
the  accountants  shall  execute  a written  undertaking  with  respect  to such
confidentiality  prior to the  commencement of any inspection.  Such examination
shall take place not more than once each year.

        4.11 In the event that an  examination  by ABBOTT of CALYPTE's  records
reveals an underpayment to ABBOTT, CALYPTE shall pay ABBOTT the deficiency, plus
interest at a rate of one percent (1%) per month from the date the  underpayment
occurred, within sixty (60) days of receiving the report of said accountants. In
the event that such  underpayment  amounts to ten  percent  (10%) or more of the
total  amount  payable for the period  examined,  CALYPTE  shall also  reimburse
ABBOTT for all reasonable out-of-pocket expenses of the examination.

        5.0      TRANSFERABILITY OF RIGHTS AND OBLIGATIONS.

        5.1  This  Agreement  and the  sublicense  granted  under it may not be
assigned or sold,  wholly or in part,  by CALYPTE  without  the express  written
consent of ABBOTT,  except that  CALYPTE  may assign its rights and  obligations
hereunder in connection with any merger,  reorganization,  or consolidation with
or into another entity, or any sale or transfer of any of its assets or business
or to any other  person or entity  or a  "change  of  control",  as that term is
defined in  Section  1.1 of this  Agreement  with the prior  written  consent of
ABBOTT.  If CALYPTE  desires to assign or sell this  Agreement  in an event that
requires  ABBOTT's  express  written  consent and ABBOTT  denies  such  consent,
CALYPTE may, in its sole discretion, purchase the right from ABBOTT to make such
assignment or sale for the sum of (a) one million dollars ($1,000,000.00) if the


                                      11




acquiring  company  is  an  EXCLUDED  COMPANY  or  ARMKEL  or  CHURCH  &  DWIGHT
CORPORATION;  or, (b) five hundred thousand dollars ($500,000.00) if the company
is  not  an  EXCLUDED  COMPANY  or  ARMKEL  or  CHURCH  &  DWIGHT   CORPORATION.
Notwithstanding  the  foregoing,  CALYPTE  shall,  however,  have  the  right to
transfer its rights granted hereunder without the need for prior written consent
from ABBOTT to any of its current  shareholders  or a private  equity fund or an
institutional investment fund or other such investor or investor group which may
purchase an equity ownership position in CALYPTE such that a "change in control"
as defined in Section 1.1 of this Agreement  occurs.  Such transfer of rights by
CALYPTE to current  shareholders  or a private  equity fund or an  institutional
investment  fund or other such investor or investor group shall be at no cost to
CALYPTE and ABBOTT's consent shall not be required.

        5.2 ABBOTT may freely assign this Agreement in whole or in part and any
or all of the rights to LICENSED PATENTS.

        5.3 This  Agreement and each and every one of the terms and  conditions
thereof,  shall  inure to the  benefit  of and be  binding  upon  the  permitted
successors and assignees of both parties.

        6.0      NOTICE.

        6.1 Any notice, payment,  report, or other correspondence  (hereinafter
collectively referred to as "correspondence")  required or permitted to be given
hereunder  shall be mailed by  certified  mail or delivery by hand or  overnight
courier to the party to whom such  correspondence is required or permitted to be
given hereunder.  If mailed,  any such notice shall be deemed to have been given
when received by the party to whom such correspondence is given, as evidenced by
written and dated receipt of the receiving party.


                                      12




        6.2 Alternatively, any correspondence provided for this Agreement shall
be deemed  sufficiently given by the party sending the correspondence  when sent
by  facsimile  to  the  party  to  whom  the  correspondence  is  addressed.   A
confirmation copy of the correspondence  will be sent by Certified or Registered
Mail. The date of the facsimile transmission will constitute the date of receipt
of the  correspondence  if an acknowledgment of the receipt of the proper number
of pages is obtained from the receiving instrument.

                 All correspondence to ABBOTT shall be addressed as follows:

                          ABBOTT LABORATORIES
                          Director, Global Licensing
                          Dept. 9RK, Bldg. AP6C
                          Diagnostics Division
                          100 Abbott Park Road
                          Abbott Park, Illinois  60064-6094
                          Fax No.:  847-937-6951

                 with a copy to:

                          ABBOTT LABORATORIES
                          Vice President, Domestic Legal
                          Dept. 322, Bldg. AP6D
                          100 Abbott Park Road
                          Abbott Park, Illinois  60064-6049
                          Fax No.:  847-938-1206

                 All correspondence to CALYPTE shall be addressed as follows:

                          CALYPTE BIOMEDICAL CORPORATION
                          5000 Hopyard road, Suite 480
                          Pleasanton, California  94588
                          Attention:  Chief Financial Officer
                          Fax No.:  775-254-5118

                 Either party may change the address to which correspondence to
it is to be addressed by written notification as provided for herein.


                                      13




        7.0      TERMINATION.

        7.1 ABBOTT shall have the right to terminate  this Agreement if CALYPTE
has  materially  defaulted  in the  performance  of any of its  royalty  payment
obligations herein contained,  and such default has not been cured within thirty
(30) days after written notice from ABBOTT affirming its intention to terminate.
For clarification purposes, a breach of any representation or warranty contained
in Article 9 shall be  considered  a material  breach for the  purposes  of this
Section  7.1.  CALYPTE  shall have the right to  complete  the  manufacture  and
distribution of PRODUCTS that have been partially manufactured as of the date of
termination.

        7.2 In the event that CALYPTE shall be  adjudicated  bankrupt,  go into
liquidation,  receivership or trusteeship, make a composition with its creditors
or enter into any  similar  proceeding  of the same  nature,  and such status or
proceeding  is not  vacated  or  terminated  within  sixty  (60) days  after its
commencement or institution,  then ABBOTT shall have the right without liability
therefor to terminate this Agreement forthwith by notice in writing to CALYPTE.

        7.3 CALYPTE shall have the right to terminate its  sublicense by giving
thirty (30) days advance written notice.  CALYPTE shall be obligated for royalty
payments under Section 4.1 for any PRODUCT sold or OTHERWISE  DISPOSED OF during
such thirty (30) day notice period.

        7.4  ABBOTT  shall have the right to  terminate  this  Agreement,  on a
country-by-country  basis, if CALYPTE,  after the Effective  Date,  institutes a
suit,  nullity  action,  opposition to grant,  or other legal action  seeking to
invalidate  the  claims  of a  LICENSED  PATENT  in that  country,  or  actively
participates (other than by legal compulsion) in any of the foregoing. CALYPTE's
payment  obligations  under Section 4.1(a) shall survive any termination of this
Agreement by CALYPTE on or prior to December 31, 2005 and the  cumulative  total
of any  remaining  installments  shall become due within thirty (30) days of the
effective date of such early termination.


                                      14




        7.5 If there is a  potential  change of control of CALYPTE to any third
party except an entity that has been an Affiliate of CALYPTE since the Effective
Date,  then CALYPTE shall  promptly  notify ABBOTT of such  potential  change of
control,  including  the identity of the third  party.  For the purposes of this
Agreement,  a "change of control"  shall mean as that term is defined in Section
1.1 of this Agreement.

        8.0      GOVERNING LAW.

        8.1 This Agreement shall be governed by, interpreted in accordance with
and enforced under the laws of the State of Illinois,  U.S.A. (regardless of its
or any other  jurisdiction's  choice of law principles),  or, as necessary,  the
laws of the  United  States of America  or the laws of the  appropriate  foreign
country if the issue is the scope or  validity of the patent  rights  granted by
that country.

        9.0      REPRESENTATIONS WARRANTIES AND LIMITATIONS.

        9.1      Nothing in this Agreement shall be construed as:

                 (a) A warranty or  representation by ABBOTT as to the validity
or enforceability of any LICENSED PATENTS; or

                 (b) A warranty or representation by ABBOTT that anything made,
used,  sold or  OTHERWISE  DISPOSED  OF under  the  sublicense  granted  in this
Agreement,  is or will be free from  infringement  of patents or other rights of
third parties; or

                 (c)  A   requirement   that  ABBOTT   shall  file  any  patent
application or secure any patent; or

                 (d) An  obligation  of  either  party to  bring  or  prosecute
actions or suits against third parties for infringement of any patents; or

                 (e) Conferring a right to use in  advertising,  publicity,  or
the like any name, tradename, or trademark of CALYPTE or ABBOTT; or


                                      15




                 (f)  Granting  by  implication,   estoppel  or  otherwise  any
licenses  or rights  under any  letters  patents  and  applications  for letters
patents other than under the LICENSED PATENTS; or

                 (g) An obligation  by ABBOTT to furnish  know-how or any other
technical information not disclosed in the LICENSED PATENTS.

        9.2 ABBOTT represents to CALYPTE that ABBOTT is the exclusive  licensee
of the LICENSED PATENTS and has the right to grant the sublicense hereunder. 9.3
Each party  represents and warrants that it has full authority to enter into and
become  bound  by the  terms  and  conditions  of this  Agreement  and  that its
execution of this Agreement will not violate,  contravene or be in conflict with
any law, rule,  by-law,  article of  incorporation,  order,  regulation or other
agreement.

        9.4 CALYPTE  represents  and warrants  that its  cumulative  historical
sales  of  the  PRODUCTS  are  less  than  or  equal  to  one  million   dollars
($1,000,000.00) prior to the EFFECTIVE DATE.

        10.0     DISCLAIMER AND HOLD HARMLESS PROVISION.

        10.1 It is understood and agreed by and between the parties hereto that
nothing  contained  in  this  Agreement  shall  constitute  or be  construed  to
constitute any undertaking,  representation,  suggestion,  inducement, warranty,
assurance or guarantee whatsoever by either party regarding the safety, quality,
yield, production, cost, profit, saleability,  licenseability,  demand, utility,
performance,  availability of raw materials,  or potential of accident or injury
to person or  property of PRODUCTS  or any assay,  product,  material,  service,
process or apparatus related to PRODUCTS.

        10.2 CALYPTE  expressly  indemnifies and holds ABBOTT,  its AFFILIATES,
successors, and assigns and its officers,  directors and employees harmless from
and against any and all claims,  liabilities,  damages, costs, expenses,  and/or
actions  of any kind  whatsoever  which  arise  from or are  connected  with the
manufacture,  use, lease,  sale, or other  disposition of PRODUCTS by CALYPTE or
its AFFILIATES under the LICENSED PATENTS.


                                      16




        10.3  Neither of the parties  hereto shall be liable in damages or have
the right to cancel for any delay or default in performing hereunder (other than
delay or default in the  payment of money) if such delay or default is caused by
conditions  beyond  its  control,  including  but  not  limited  to Acts of God,
governmental restrictions, continuing domestic or international problems such as
war or insurrections,  strikes,  fires, flood, work stoppages,  embargoes and/or
other casualty or cause; provided, however, that any party hereto shall have the
right to terminate  this Agreement upon thirty (30) days prior written notice if
the other party is unable to fulfill its obligations under this Agreement due to
any of the  above-mentioned  causes and such inability continues for a period of
six (6) months.

        11.0     CAPTIONS.

        11.1 The captions and paragraph  headings of this  Agreement are solely
for the convenience of reference and shall not affect its interpretation.

        12.0     SEVERABILITY.

        12.1  Should  any  part  or  provision   of  this   Agreement  be  held
unenforceable  or in conflict with the  applicable  laws or  regulations  of any
jurisdiction,  the invalid or unenforceable  part or provision shall be replaced
with a  provision  which  accomplishes,  to the extent  possible,  the  original
business  purpose of such part or provision in a valid and  enforceable  manner,
and the  remainder  of this  Agreement  shall  remain  binding  upon the parties
hereto.

        13.0     WAIVER.

        13.1 No failure or delay on the part of a party in exercising any right
hereunder shall operate as a waiver of, or impair,  any such right. No single or
partial  exercise of any such right shall preclude any other or further exercise
thereof or the exercise of any other right. No waiver of any such right shall be
deemed a waiver of any other right hereunder.


                                      17




        14.0     SURVIVAL.

        14.1  The  provisions  of  Articles  4, 8, 9 and 10 shall  survive  the
termination  or expiration of this  Agreement and shall remain in full force and
effect. Specifically, termination or expiration shall not affect, inter alia;

                 (a) CALYPTE's  obligation to pay royalties and supply  reports
for PRODUCT sold or OTHERWISE  DISPOSED OF up to such  termination or expiration
as specified in Article 4 of this Agreement;

                 (b)  ABBOTT's  right  to  receive  or  recover  and  CALYPTE's
obligation to pay royalties  accrued or accruable for payment at the time of any
termination;

                 (c) CALYPTE's obligation to maintain records pertaining to the
NET SALES of PRODUCT sold or OTHERWISE  DISPOSED OF prior to such termination or
expiration  and  ABBOTT's  right to  conduct a final  examination  of records in
accordance  with  Section  4.10 of this  Agreement  within two (2) years of such
termination or expiration; and

                 (d)  Licenses  and  releases  running in favor of customers or
transferees of either party in respect to PRODUCT sold or OTHERWISE  DISPOSED OF
prior to termination of this Agreement.

        14.2 The provisions of this Agreement which do not survive  termination
or expiration hereof (as the case may be) shall, nonetheless, be controlling on,
and shall be used in construing and interpreting,  the rights and obligations of
the parties  hereto with regard to any dispute,  controversy  or claim which may
arise under, out of, in connection with, or relating to this Agreement.

        14.3  Notwithstanding  the above,  Article 18  (Confidentiality)  shall
survive  and remain in full force and effect for a period of five (5) years from
the effective date of termination.


                                      18




        15.0     UNLICENSED COMPETITION.

        15.1 At the  written  request of CALYPTE,  ABBOTT  shall  consider  the
enforcement of any LICENSED  PATENT against a third party  identified by CALYPTE
as a potential  infringing  third party within the TERRITORY.  ABBOTT shall take
the steps that it deems  reasonable in its sole commercial  judgement to protect
the  LICENSED  PATENTS.  Nothing  in this  Agreement  shall be  construed  as an
obligation  upon ABBOTT to enforce any LICENSED  PATENT  against any third party
within the TERRITORY.

        16.0     ENTIRE AGREEMENT.

        16.1 This  Agreement  constitutes  the  entire  agreement  between  the
parties  hereto  respecting  the  subject  matter  hereof,  and  supersedes  and
terminates all prior  agreements  respecting the subject matter hereof,  whether
written or oral, and may be amended only by an instrument in writing executed by
both parties hereto.

         17.0    DISPUTE RESOLUTION.

        17.1 The parties  recognize  that from time to time a dispute may arise
relating to either  party's  rights or  obligations  under this  Agreement.  The
parties agree that any such dispute shall be resolved by the Alternative Dispute
Resolution  ("ADR")  provisions  set forth in this Exhibit,  the result of which
shall be binding upon the parties.

                 To begin the ADR  process,  a party  first  must send  written
notice of the dispute to the other party for attempted  resolution by good faith
negotiations  between their  respective  presidents (or their  designees) of the
affected  subsidiaries,  divisions,  or business units within  twenty-eight (28)
days  after  such  notice  is  received  (all  references  to "days" in this ADR
provision  are to calendar  days).  If the matter has not been  resolved  within
twenty-eight (28) days of the notice of dispute,  or if the parties fail to meet
within such  twenty-eight (28) days, either party may initiate an ADR proceeding
as  provided  herein.  The  parties  shall have the right to be  represented  by
counsel in such a proceeding.


                                      19




        17.2 To begin an ADR  proceeding,  a party shall provide written notice
to the other  party of the issues to be resolved by ADR.  Within  fourteen  (14)
days after its receipt of such notice, the other party may, by written notice to
the party  initiating the ADR, add additional  issues to be resolved  within the
same ADR.

        17.3 Within  twenty-one (21) days following receipt of the original ADR
notice, the parties shall select a mutually acceptable neutral to preside in the
resolution of any disputes in this ADR proceeding.  If the parties are unable to
agree on a mutually  acceptable  neutral  within such  period,  either party may
request the President of the CPR Institute for Dispute Resolution  ("CPR"),  366
Madison  Avenue,  14th  Floor,  New York,  New York  10017,  to select a neutral
pursuant to the following procedures:

                 (a) The CPR  shall  submit  to the  parties a list of not less
than five (5) candidates within fourteen (14) days after receipt of the request,
along with a  Curriculum  Vitae for each  candidate.  No  candidate  shall be an
employee,  director, or shareholder of either party or any of their subsidiaries
or affiliates.

                 (b) Such list shall  include a statement of disclosure by each
candidate of any circumstances likely to affect his or her impartiality.

                 (c)  Each  party  shall  number  the  candidates  in  order of
preference  (with the number one (1)  signifying  the greatest  preference)  and
shall deliver the list to the CPR within seven (7) days following receipt of the
list of candidates.  If a party believes a conflict of interest exists regarding
any of the  candidates,  that party shall provide a written  explanation  of the
conflict to the CPR along with its list showing its order of preference  for the
candidates.  Any party failing to return a list of  preferences on time shall be
deemed to have no order of preference.

                 (d) If the parties  collectively  have  identified  fewer than
three  (3)  candidates  deemed  to have  conflicts,  the CPR  immediately  shall
designate as the neutral the  candidate for whom the parties  collectively  have
indicated  the  greatest  preference.   If  a  tie  should  result  between  two
candidates,  the CPR may designate either candidate. If the parties collectively


                                      20




have identified three (3) or more candidates  deemed to have conflicts,  the CPR
shall review the explanations  regarding  conflicts and, in its sole discretion,
may either (i)  immediately  designate as the neutral the candidate for whom the
parties collectively have indicated the greatest preference, or (ii) issue a new
list of not less than five (5)  candidates,  in which  case the  procedures  set
forth in Sections 17.3(a) - 17.3(d) shall be repeated.

        17.4 No earlier  than  twenty-eight  (28) days or later than  fifty-six
(56) days after  selection,  the neutral shall hold a hearing to resolve each of
the issues  identified by the parties.  The ADR proceeding shall take place at a
location agreed upon by the parties  [provided that if ABBOTT  initiates the ADR
then  the  venue  shall be in  SUBLICENSEE's  country/state  and if  SUBLICENSEE
initiates the ADR then the venue shall be in the  Illinois/USA].  If the parties
cannot agree,  the neutral shall  designate a location  other than the principal
place of business of either party or any of their subsidiaries or affiliates.

        17.5 At least  seven (7) days prior to the  hearing,  each party  shall
submit the following to the other party and the neutral:

                 (a) a copy of all exhibits on which such party intends to rely
in any oral or written presentation to the neutral;

                 (b) a list of any witnesses  such party intends to call at the
hearing, and a short summary of the anticipated testimony of each witness;

                 (c) a proposed  ruling on each issue to be resolved,  together
with a request for a specific  damage award or other remedy for each issue.  The
proposed  rulings and remedies  shall not contain any recitation of the facts or
any legal arguments and shall not exceed one (1) page per issue;

                 (d) a brief in support of such  party's  proposed  rulings and
remedies,  provided that the brief shall not exceed twenty (20) pages. This page
limitation  shall  apply  regardless  of the number of issues  raised in the ADR
proceeding.


                                      21




                 Except as expressly  set forth in Sections  17.5(a) - 17.5(d),
no discovery shall be required or permitted by any means, including depositions,
interrogatories, requests for admissions, or production of documents.

        17.6 The hearing  shall be  conducted on two (2)  consecutive  days and
shall be governed by the following rules:

                 (a) Each party  shall be entitled to five (5) hours of hearing
time to present its case. The neutral shall determine whether each party has had
the five (5) hours to which it is entitled.

                 (b) Each party shall be entitled, but not required, to make an
opening statement, to present regular and rebuttal testimony, documents or other
evidence,  to  cross-examine   witnesses,   and  to  make  a  closing  argument.
Cross-examination  of  witnesses  shall occur  immediately  after  their  direct
testimony,  and  cross-examination  time  shall be  charged  against  the  party
conducting the cross-examination.

                 (c) The party  initiating the ADR shall begin the hearing and,
if it chooses to make an opening  statement,  shall  address  not only issues it
raised but also any issues raised by the responding party. The responding party,
if it chooses to make an opening statement, also shall address all issues raised
in the ADR.  Thereafter,  the presentation of regular and rebuttal testimony and
documents,  other  evidence,  and closing  arguments  shall  proceed in the same
sequence.

                 (d) Except when  testifying,  witnesses shall be excluded from
the hearing until closing arguments.

                 (e) Settlement  negotiations,  including any  statements  made
therein,  shall not be admissible under any circumstances.  Affidavits  prepared
for  purposes of the ADR hearing also shall not be  admissible.  As to all other
matters,  the neutral shall have sole discretion  regarding the admissibility of
any evidence.

        17.7 Within seven (7) days  following  completion of the hearing,  each
party may  submit to the other  party and the  neutral a  post-hearing  brief in
support of its proposed rulings and remedies, provided that such brief shall not


                                      22




contain or discuss any new  evidence  and shall not exceed ten (10) pages.  This
page limitation shall apply regardless of the number of issues raised in the ADR
proceeding.

        17.8 The neutral shall rule on each disputed issue within fourteen (14)
days  following  completion  of the  hearing.  Such  ruling  shall  adopt in its
entirety the proposed  ruling and remedy of one of the parties on each  disputed
issue but may adopt one party's proposed rulings and remedies on some issues and
the other party's  proposed  rulings and remedies on other  issues.  The neutral
shall  not issue any  written  opinion  or  otherwise  explain  the basis of the
ruling.

        17.9 The neutral shall be paid a reasonable  fee plus  expenses.  These
fees and  expenses,  along with the  reasonable  legal fees and  expenses of the
prevailing party (including all expert witness fees and expenses),  the fees and
expenses of a court reporter, and any expenses for a hearing room, shall be paid
as follows:

                 (a) If the neutral rules in favor of one party on all disputed
issues in the ADR, the losing party shall pay 100% of such fees and expenses.

                 (b) If the neutral  rules in favor of one party on some issues
and the other party on other issues,  the neutral shall issue with the rulings a
written  determination  as to how such  fees  and  expenses  shall be  allocated
between the parties.  The neutral shall allocate fees and expenses in a way that
bears a  reasonable  relationship  to the  outcome  of the ADR,  with the  party
prevailing on more issues, or on issues of greater value or gravity,  recovering
a relatively larger share of its legal fees and expenses.

        17.10  The  rulings  of the  neutral  and the  allocation  of fees  and
expenses  shall  be  binding,  non-reviewable,  and  non-appealable,  and may be
entered as a final  judgment in any court having  jurisdiction.  


                                      23




        17.11  Except as  provided  in Article 17 or as  required  by law,  the
existence of the dispute,  any  settlement  negotiations,  the ADR hearing,  any
submissions (including exhibits,  testimony,  proposed rulings, and briefs), and
the rulings shall be deemed Confidential Information. The neutral shall have the
authority  to impose  sanctions  for  unauthorized  disclosure  of  Confidential
Information.

        17.12 The ADR proceedings shall be conducted in the English language.

        17.13 Notwithstanding any of the above, this Article 17 shall not apply
to, and no ADR proceeding  shall deal with,  disputes  relating to the issues of
the validity and/or enforceability of any of the LICENSED PATENTS.

        18.0     CONFIDENTIALITY.  

         18.1 This  Agreement,  its terms,  and any  information  provided by a
party hereto pursuant to this Agreement,  shall be kept in strictest  confidence
by the parties  hereto except that the parties  hereto may disclose the terms of
the  Agreement  as required by law, to  prospective  purchasers  of the business
relating to  PRODUCTS;  provided  that any such  persons to whom  disclosure  is
permitted have agreed to keep such terms confidential. Except as provided above,
no party hereto shall  provide this  Agreement or any of its terms to any person
or entity not a party  hereto.  Notwithstanding  any of the above,  the  parties
hereto may  disclose  publicly  that  ABBOTT has  granted  and  SUBLICENSEE  has
accepted a  non-exclusive  right and sublicense  under the LICENSED  PATENTS and
such other terms of the  Agreement as that party deems  necessary to comply with
SEC and applicable stock exchange disclosure rules.

         18.2 Notwithstanding  Section 18.1, if either of the parties hereto is
required (by deposition, questions, interrogatories, requests for information or
documents  as  required  by  or  in  any  legal  proceedings,  subpoenas,  civil
investigative  demands,  or any other similar compulsory  Processes) to disclose
any of the terms of this  Agreement,  each party so required  shall  provide the
other party with prompt  written  notice of any such request or  requirement  so
that such other party may seek a protective order or other appropriate remedy or
waive compliance with the provisions of Section 18.1 of this Agreement.


                                      24




        18.3  Notwithstanding  the  foregoing,  neither of the parties shall be
prohibited from disclosing the terms of this Agreement in a Quarterly  Report on
Form 10-Q or Annual  Report on Form 10-K,  if upon the advice of legal  counsel,
such  disclosure is required by the rules and  regulations of the Securities and
Exchange Commission, including but not limited to Regulations S-K and S-X.

IN WITNESS WHEREOF, the parties hereto have caused this Agreement to be executed
by their respective officers thereunto duly authorized to be effective as of the
EFFECTIVE DATE.

Calypte Biomedical Corporation

By:  /s/ Richard D. Brounstein                  
  ---------------------------------------------

Name:  Richard D. Brounstein                    
    -------------------------------------------

Title:   EVP & CFO                              
     ------------------------------------------

Date:  6/28/04                                  
    -------------------------------------------

ABBOTT LABORATORIES

By:  /s/ Joseph M. Nemmers Jr.                  
  ---------------------------------------------
    Joseph M. Nemmers Jr.
    Sr. Vice President, Diagnostic Operations
    President, Abbott Diagnostics Division

Date:  6/21/04                                  
    -------------------------------------------


                                      25




                                  APPENDIX A

U.S. Patent No.  5,073,484 -- Issued December 17, 1991 U.S. Patent No. 5,654,162
-- Issued August 5, 1997 U.S. Patent No. 6,020,147 -- Issued February 1, 2000

Foreign counterparts:

        Country                   Pat./Appln. No.          Issue/Filing Date
        -------                   ---------------          -----------------
        Australia                 121983                   03/09/83
        Belgium                   88636                    03/09/83
        Germany                   88636                    03/09/83
        France                    88636                    03/09/83
        United Kingdom            88636                    03/09/83
        Israel                    68082                    04/01/87
        Italy                     88636                    03/09/83
        Japan                     1952845                  07/28/95
        Japan                     2139664                  12/25/98
        Japan                     2913281                  04/16/99
        Luxembourg                88636                    03/09/83
        South Africa              831617                   03/28/84




                                      26







                                                                   EXHIBIT 31.1


             CERTIFICATION OF CHIEF EXECUTIVE OFFICER PURSUANT TO

                 SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002

I, J. Richard George, certify that:

1. I have reviewed  this  quarterly  report on Form  10-QSB/A  (No.1) of Calypte
Biomedical Corporation;

2. Based on my  knowledge,  this  quarterly  report  does not contain any untrue
statement of a material fact or omit to state a material fact  necessary to make
the statements made, in light of the  circumstances  under which such statements
were made, not  misleading  with respect to the period covered by this quarterly
report;

3.  Based  on my  knowledge,  the  financial  statements,  and  other  financial
information  included in this quarterly  report,  fairly present in all material
respects the financial  condition,  results of operations  and cash flows of the
registrant as of, and for, the periods presented in this quarterly report;

4.  The  registrant's  other  certifying  officers  and  I are  responsible  for
establishing and maintaining  disclosure  controls and procedures (as defined in
Exchange Act Rules 13a-14 and 15d-14) for the registrant and we have:

        a) designed such  disclosure  controls and  procedures,  or caused such
disclosure  controls and  procedures to be designed,  under our  supervision  to
ensure that  material  information  relating to the  registrant,  including  its
consolidated subsidiaries,  is made known to us by others within those entities,
particularly during the period in which this quarterly report is being prepared;

        b) evaluated the effectiveness of the registrant's  disclosure controls
and  procedures,  and  presented  in  this  report  our  conclusions  about  the
effectiveness  of the disclosure  controls and procedures,  as of the end of the
period covered by this report based on such evaluation; and

        c)  disclosed  in this report any change in the  registrant's  internal
control over financial  reporting  that occurred  during the  registrant's  most
recent fiscal quarter (the registrant's  fourth fiscal quarter in the case of an
annual  report)  that  has  materially  affected,  or is  reasonably  likely  to
materially affect, the registrant's  internal control over financial  reporting;
and;

5. The registrant's other certifying officers and I have disclosed, based on our
most recent  evaluation of internal  control over  financial  reporting,  to the
registrant's auditors and the audit committee of registrant's board of directors
(or persons performing the equivalent function):

        a) all significant  deficiencies and material  weaknesses in the design
or operation of internal controls over financial  reporting which are reasonably
likely  to  adversely  affect  the  registrant's  ability  to  record,  process,
summarize and report financial information; and

        b) any fraud,  whether or not  material,  that  involves  management or
other employees who have a significant role in the registrant's internal control
over financial reporting.

Date: December 17, 2004

/s/ J. Richard George
--------------------------
J. Richard George
President and Chief Executive Officer






                                                                   EXHIBIT 31.2


             CERTIFICATION OF CHIEF FINANCIAL OFFICER PURSUANT TO
                 SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002

I, Richard D. Brounstein, certify that:

1. I have reviewed  this  quarterly  report on Form  10-QSB/A  (No.1) of Calypte
Biomedical Corporation;

2. Based on my  knowledge,  this  quarterly  report  does not contain any untrue
statement of a material fact or omit to state a material fact  necessary to make
the statements made, in light of the  circumstances  under which such statements
were made, not  misleading  with respect to the period covered by this quarterly
report;

3.  Based  on my  knowledge,  the  financial  statements,  and  other  financial
information  included in this quarterly  report,  fairly present in all material
respects the financial  condition,  results of operations  and cash flows of the
registrant as of, and for, the periods presented in this quarterly report;

4.  The  registrant's  other  certifying  officers  and  I are  responsible  for
establishing and maintaining  disclosure  controls and procedures (as defined in
Exchange Act Rules 13a-14 and 15d-14) for the registrant and we have:

        a) designed such  disclosure  controls and  procedures,  or caused such
disclosure  controls and  procedures to be designed,  under our  supervision  to
ensure that  material  information  relating to the  registrant,  including  its
consolidated subsidiaries,  is made known to us by others within those entities,
particularly during the period in which this quarterly report is being prepared;

        b) evaluated the effectiveness of the registrant's  disclosure controls
and  procedures,  and  presented  in  this  report  our  conclusions  about  the
effectiveness  of the disclosure  controls and procedures,  as of the end of the
period covered by this report based on such evaluation; and

        c)  disclosed  in this report any change in the  registrant's  internal
control over financial  reporting  that occurred  during the  registrant's  most
recent fiscal quarter (the registrant's  fourth fiscal quarter in the case of an
annual  report)  that  has  materially  affected,  or is  reasonably  likely  to
materially affect, the registrant's  internal control over financial  reporting;
and;

5. The registrant's other certifying officers and I have disclosed, based on our
most recent  evaluation of internal  control over  financial  reporting,  to the
registrant's auditors and the audit committee of registrant's board of directors
(or persons performing the equivalent function):

        a) all significant  deficiencies and material  weaknesses in the design
or operation of internal controls over financial  reporting which are reasonably
likely  to  adversely  affect  the  registrant's  ability  to  record,  process,
summarize and report financial information; and

        b) any fraud,  whether or not  material,  that  involves  management or
other employees who have a significant role in the registrant's internal control
over financial reporting.

Date: December 17, 2004

/s/ Richard D. Brounstein
-----------------------------
Richard D. Brounstein
Executive Vice President and Chief Financial Officer


 

wer soll das bitte lesen, da du es ja reinkopiert hast, gibts da vielleicht eine short diary über diese aktie ?? bin keine lesemaus! wenns geht bitte auf deutsch  

Gruß

C.O  

0,33 $
Its not a trick ! its a Caly !!!!!!!!!!!!!!!!!!!

Position- Long; ST Rating- Strong Buy; LT Rating- Strong Buy

 

 

 

Position- Long; ST Rating- Strong Buy; LT Rating- Strong Buy

 

uns wieder so richtig Freude ;-)  

 

Position- Long; ST Rating- Strong Buy; LT Rating- Strong Buy

 

Position- Long; ST Rating- Strong Buy; LT Rating- Strong Buy

 

Position- Long; ST Rating- Strong Buy; LT Rating- Strong Buy

 

Position- Long; ST Rating- Strong Buy; LT Rating- Strong Buy

 

Position- Long; ST Rating- Strong Buy; LT Rating- Strong Buy

 

 

 

VERDÜNNUNG ? nicht dieses Mal, überprüft hier SEC-Feilstaub
SB-2/A
CALYPTE BIOMEDICAL HANDELSGESELLSCHAFT legte diese Form SB-2/A am 12/20/04 ab
Seite 31>

Der Kurs müsste springen nach meiner Meinung, warten wir auf Morgen bis das ganze realisiert wird.

Gruß

C.O
 

 

die ellenlangen Filings brauchst du nicht einzustellen,
nimmt nur Platz weg!
Wir wissen auch wo die zu finden sind!
Nichts böse gemeint!!!  

Die mit dem Unternehmen auf anhib nichts anfangen können, na ja werde in zukunft mich kommplett zürück ziehen

Gruß

C.O  

!!! Grüße